What is INT230-6?
INT230-6 is a multi-agent (more than one medication co-formulated together) product specifically designed to be directly injected into tumors. The first two compounds, cisplatin and vinblastine sulfate, are commercial potent agents that are normally given intravenously during chemotherapy and are used to treat several types of cancer. The third ingredient comprising INT230-6 is a penetration enhancer. This compound allows the first two ingredients to disperse throughout the tumor and move directly into the cancer cells.
How is the new drug used?
INT230-6 is injected directly into the tumor(s). Multiple tumors can be treated in one session. Any type of tumor accessible by a needle could potentially be treated. Participants in our Phase 1/2 clinical study currently are dosed every two weeks for a total of 5 treatments over about 2 months. Retreatment is possible pending results of the first 5 doses. Fourteen different cancer types have been treated to date including; adenoid cystic, adrenal cortical carcinoma, bile duct, breast cancer, colon cancer, chordoma, head and neck, liver metastases, lymphoma, melanoma, ovarian cancer, pancreatic cancer, squamous cell carcinoma, sarcoma, and thyroid cancer.